New wound dressing could speed healing after breast reduction
NCT ID NCT06725459
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tests whether a closed incision negative pressure wound therapy (ciNPWT) device can reduce wound complications after breast reduction surgery. 92 women will have one breast treated with the device and the other with standard adhesive strips. The goal is to see if the device leads to fewer infections, less pain, and better scar quality.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- Closed incision negative pressure wound therapy (ciNPWT) device
- What this could lead to
- If it works, this could mean fewer wound problems and better healing after breast reduction surgery.
- What could go wrong
- This is a small, early-stage trial with only 92 participants, so results may not apply to everyone. The device is used for just 7 days, and long-term benefits are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medstar Georgetown University Hospital
RECRUITINGWashington D.C., District of Columbia, 20007, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test